Who we are

MexBrain is a clinical-stage company developing treatments against conditions involving metals toxicity (iron, copper, lead, etc.). The company is a spin-off from the University of Lyon and has its offices in France. MexBrain's lead compound, MEX-CD1, is a novel superchelating polymer that can be used with a dialysis machine, as a medical device, to extract free metals from the blood. The clinical development is focused on two first indications, Wilson's Disease and Acute Kidney Injury (AKI).

The company is conducting two pilot clinical trials in Europe (MEXWILS and MEXACLF) to assess the effect of MEX-CD1 on reducing free metal content in the bloodstream of patients with acute conditions. Both trials are currently recruiting.